Anti-malignin antibody in serum (AMAS) is a test offered by only one laboratory in the U.S. While it is described by its manufacturer as useful in early diagnosis for those at high risk for cancer and in monitoring cancer progression, there is little published evidence from independent sources to support this claim. Despite more than 20 years of availability, the test has not earned the confidence of most in the medical community given the lack of data regarding its clinical utility.

?
Ask Question
AboutMyClinic
SmartSite created on AboutMyClinic.com
Disclaimer: The health-related content provided here may be generated or assisted by Artificial Intelligence (AI) and is intended for general informational and educational purposes only. It should not be considered a substitute for professional medical advice, diagnosis, or treatment.